gp130胸外区近膜端缺失的突变体介导IL—6信号的研究

研究ｇｐ１３０胸外区远膜端和近膜端在ＩＬ－６信号转导的作用，方法用分子克隆手段构建全长的膜结合型ｇｐ１３０分子和胸外区第３０１－５８２位氨基酸残 的突变体分子，并通过阻滞电泳方法比较突变体与野生型分子在传导信号方面的差异。     

可溶性gp130和gp130反义核酸对IL-6诱导的靶基因启动子活性的影响

ｇｐ１３０是ＩＬ－６信号转导子，ＩＬ－６介导的信号转导起始于ｇｐ１３０与ＩＬ－６、ＩＬ－６Ｒα形成的复合物。为了研究ｇｐ１３０胞外区的结构与功能，在肝癌细胞ＨｅｐＧ２中建立了检测ＩＬ－６诱导基因表达强弱的方法，并观察了含胞外区全长（５９７个氨基酸）及氨基端３０４个氨基酸残基的ｇｐ１３０突变体，以及ｇｐ１３０反义核酸对ＩＬ－６生物学效应的影响。证明两个突变体和反义核酸均拮抗ＩＬ－６信号，为进一步研究ＩＬ－６受体拮抗剂奠定了基础。     

肝炎肝硬化患者血清sIL—6R和sgp130变化的研究

为了探讨肝炎肝硬化（ＨＣ）患者血清可溶性白介素６受体（ｓＩＬ－６Ｒ）和可溶性ｇｐ１３０（ｓｇｐ１３０）含量的变化及其临床意义，运用酶联免疫吸附法检测了３４例ＨＣ患者血清ｓＩＬ－６Ｒ和ｓｇｐｌ３０含量。结果表明：①活动性和静止性ＨＣ患者血清ｓＩＬ－６Ｒ和ｓｇｐ１３０水平均高于正常对照（Ｐ＜０．０１），ｓＩＬ－６Ｒ／ｓｇｐ１３０比值ＨＣ患者低于正常人，活动性ＨＣ患者低于静止性ＨＣ患者（Ｐ＜０．０１）；②血清ｓＩＬ－６Ｒ和ｓｇｐ１３０水平之间呈正相关（ｒ＝０．４１７，Ｐ＜０．０５），ｓＩＬ－６Ｒ、ｓｇｐｌ３０水平与血清Ｂｉｌ－Ｔ水平间亦呈正相关（分别为ｒ＝０．４７４，ｒ＝０．４８２，Ｐ＜０．０１），而与血清ＡＬＴ水平无明显相关性（分别为ｒ＝０．１９３，ｒ＝０．１５２，Ｐ＞０．０５）。提示：血清ｓＩＬ－６Ｒ、ｓｇｐ１３０与ＨＣ的病情演变有关     

GP130与IL-6信号途径

IL-6受体两个亚基IL-6Rα和gp130组成。IL-6与之形成三元复合体,然后激活与gp130相偶联的Jak家族的酪氨酸激酶,诱发系列的磷酸化事件,激活Ras途径及新发现的不依赖Ras的途径,即直接激活STAT家族成员APRF等,然后,诱导靶基因表达。     

可溶性gp130酶联检测试剂盒的研制及其运用

目的 :建立灵敏、特异、稳定和简便的人可溶性gp130 (sgp130 )酶标检测试剂盒。方法 :采用本室制备的鼠抗人gp130单抗T2作为包被单抗 ,另一株识别不同抗原位点的单抗T12经生物素 (biotin)标记后作为检测抗体 ,建立双单抗夹心的人sgp130酶标检测方法 ,并分别测定了 40例健康供血员、40例甲亢及 47例慢性肾炎患者血清中sgp130的含量。结果 :成功地研制了人sgp130酶联检测试剂盒 ,其灵敏度为 10ng/ml。该试剂盒 4℃放置 3个月 ,离散度 (CV) <± 7 6 %,回收率为95 %～ 111%,提示检测方法具有良好的灵敏度、稳定性和准确性。用该试剂盒测得的血清中sgp130含量的 95 %正常值范围为5 36 92～ 2 87 88(ng/ml) ,甲亢及慢性肾炎患者血清中sgp130的含量分别为 937 16± 2 17 5 9和 80 6 4 5± 138 4 7(ng/ml) ,明显高于正常对照者 (P <0 0 1)。结论 :建立的人sgp130酶标检测试剂盒 ,能够对血清中sgp130进行准确定量 ,可为临床gp130相关性疾病的辅助诊断、疗效估价和判断预后提供有价值的生物学参数 ,具有良好的运用前景。     

可溶性白细胞介素6受体β亚基拮抗IL—6信号的研究

ｇｐ１３０是白细胞介素６（ＩＬ－６）受体的β亚基和信号转导子。ＩＬ－６介导的信号转导起始于ｇｐ１３０与ＩＬ－６、ＩＬ－６Ｒα形成的复合体。为了研究ｇｐ１３０胞外区的结构与功能，我们克隆并表达了其胞外区全长及氨基端３０４个氨基酸残基的片段，并在白血病Ｒ２细胞、杂交瘤细胞和肝癌细胞中观察其生物学效应。结果发现，两个片段均拮抗ＩＬ－６信号，从而，证明了含细胞因子结合区的可溶性小片段和大片段都能与膜结合型     

gp130及其介导的信号转导

ｇｐ１３０是ＩＬ－６等细胞因子的共有信号传导链，其胞浆区具有在细胞因子受体家族中有一定保守性的ＢＯＸ１、ＢＯＸ２和ＢＯＸ３，在信号传导中具有重要作用。已知ｇｐ１３０通过ＪＡＫ－Ｓｔａｔ途径和ＭＡＰ激酶途径传导信号。但不能激活上述两条途径的ｇｐ１３０截断变异体仍可传导增殖信号，表明有其它ｇｐ１３０信号传导途径存在。     

gp130的结构、功能及信号传导

gp130是IL-6家族细胞因子共用的受体和信号转导子,弄清gp130结构与功能的关系以及gp130介导的信号途径,对于阐明IL-6家族不同因子作用的特异性具有十分重要的意义。本文就gp130结构、功能及其信号传导等方面的最新进展进行了简要综述。     

可溶性gp130(sgp130)在IL-6/IL-6R系统中的生物学作用研究

目的：在成功克隆、表达和纯化人可溶性ｇｐ１３０（ｓｇｐ１３０）分子的基础上,研究ｓｇｐ１３０在白介素６（ＩＬ６）／白介素６受体（ＩＬ６Ｒ）系统中的生物学作用。方法：采用转人膜型ｇｐ１３０的ＢＡＦ１３０细胞和人多发性骨髓瘤（ＭＭ）细胞株ＸＧ４ＣＮＴＦ和分离得到新鲜ＭＭ细胞,通过３ＨＴｄＲ的掺入做生物学检测,观察ｓｇｐ１３０在上述细胞上对ＩＬ６生物学活性的影响。结果：ｓｇｐ１３０对ＩＬ６和可溶性ＩＬ６Ｒ引起ＢＡＦ１３０细胞的增殖有抑制作用。此外,ｓｇｐ１３０对ＩＬ６刺激ＸＧ４ＣＮＴＦ细胞和分离得到新鲜ＭＭ细胞的增殖也有抑制作用。结论：ｓｇｐ１３０为ＩＬ６的拮抗剂。     

胃癌组织中GST—π表达及其意义

为了解胃癌组织中谷胱甘肽Ｓ－转移酶－π表达的临床意义，运用流式细胞技术，对７５例胃癌组织及癌旁粘膜组织中ＧＳＴ－π的表达进行了检测；同 免疫组化检测胃癌组织中Ｃ－ｅｒＢ－２蛋白和ｎｍ２３蛋白。     

Activation of the gp130 signaling pathway by monoclonal antibodies directed against the gp130 molecule

Six cytokines of the interleukin (IL)-6 family involved in various inflammatory or tumoral diseases share the same gp130 signal transducer chain. We made a panel of anti-gp130 monoclonal antibodies (mAb) to study the structure and function of the gp130 molecule. These mAb recognized different epitopes of the gp130 that we called A to J. Most of the mAb were found to be inhibitors and we studied whether some of them could also induce gp130 activation. When used alone, none of them was able to initiate the proliferation of IL-6-dependent cell lines. However, some particular associations of the mAb were able to induce a proliferative response. mAb B1 could activate the lines in association with F1 or with I2 but not with I1, which in ELISA was similar to I2. In contrast mAb B2, which in ELISA appeared to be very similar to B1, was able to activate the cells in association with I1 but not with F1 or I2. Two other mAb belonging to specificities A and C were found to be activators either in association with I1 only, or with I1 or B2, respectively. These associations of mAb appeared to be nearly as potent activators as IL-6 itself. Although we still have no precise idea of the mechanisms involved, they are interesting tools to study the molecular interactions leading to gp130 activation and, from a practical point of view, valuable growth factors of hematopoietic stem cells.     

A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease

The presence and the role of soluble gp130, the soluble form of a component of the interleukin (IL)-6 receptor complex, were investigated in inflammatory bowel disease. The serum concentrations of soluble gp130 were increased in ulcerative colitis (active disease, median, 93.5 ng/ml; interquartile range, 26-125 ng/ml; inactive disease, 81 ng/ml, 24.8-137.3 ng/ml) and to a lesser extent in Crohn's disease (active disease, 66 ng/ml, 44.4-87.6 ng/ml; inactive disease, 63 ng/ml, 43.5-82.5 ng/ml) compared to normal controls (43 ng/ml, 27-59 ng/ml). Paired analysis of serum samples showed a decrease of IL-6 and soluble IL-6 receptor concentrations in both diseases and an increase of soluble gp130 concentrations, especially in ulcerative colitis, just after the resolution of disease exacerbation. Size fractionation of the serum revealed that a part of the IL-6 co-eluted with soluble gp130 and soluble IL-6 receptor. The IL-6-induced proliferation of murine B9 hybridoma was enhanced by recombinant soluble IL-6 receptor, whereas the proliferation was inhibited by recombinant soluble gp130. These results indicate that soluble gp130 may function as a natural inhibitor of the IL-6 actions in inflammatory bowel disease.     

人可溶性IL-6R基因在COS7细胞中的表达及活性分析

目的在ＣＯＳ７细胞中表达具有生物学功能的人可溶性ＩＬ－６Ｒ（ｓＩＬ－６Ｒ），作为研究ｓＩＬ－６Ｒ结构与功能关系的基础。方法首先利用ＰＣＲ技术扩增出人可溶性ＩＬ－６Ｒ（ｈｓＩＬ－６Ｒ）编码基因片段，并重组入克隆载体ｐＡＬＴＥＲ－１。通过基因序列分析确定了目的基因的核苷酸序列，并进一步构建了由ＳＶ４０晚期启动子和ＨＣＭＶ早期启动子控制的表达质粒ｐＳＶＬ６Ｒ和ｐＣＭＶ６Ｒ。用脂质体介导的方法将表达质粒转染ＣＯＳ７细胞，并分别在ｍＲＮＡ水平（斑点杂交）和蛋白水平（ＥＬＩＳＡ和Ｗｅｓｔｅｒｎ－ｂｌｏｔ）检测ｓＩＬ－６Ｒ基因在ＣＯＳ７细胞中的表达。在７ＴＤ１，ＬＴ１２两种ＩＬ－６反应细胞系上检测转染细胞上清（含ｓＩＬ－６Ｒ）的生物学活性。结果在ｍＲＮＡ水平和蛋白水平分别检测到ｓＩＬ－６Ｒ基因在ＣＯＳ７细胞中的表达，表达产物分子量约为５００００。表达产物在７ＴＤ１，ＬＴ１２细胞系上检测到明显的生物学活性。结论天然ｓＩＬ－６Ｒ基因在ＣＯＳ７细胞中的成功表达为进一步制备ｓＩＬ－６Ｒ突变体及其结构与功能关系的研究奠定了基础     

High circulating levels of biologically inactive IL-6/SIL-6 receptor complexes in systemic juvenile idiopathic arthritis: evidence for serum factors interfering with the binding to gp130

We previously demonstrated that high levels of IL-6/sIL-6R complexes are present in sera of patients with systemic juvenile idiopathic arthritis (s-JIA) and that the amount of IL-6 estimated in the IL-6/sIL-6R complexes is markedly higher than that measured by the B9 assay. Here, we show that two additional bioassays, employing human myeloma XG-1 cells and human hepatoma Hep3B cells, detected serum IL-6 levels similar to those measured by the B9 assay and approximately 10-fold lower than the IL-6 levels estimated to be present in the IL-6/sIL-6R complex. Using an assay for the measurement of the amount of circulating IL-6 complexed with the sIL-6R and available for binding to gp130 (gp130 binding activity), we show that the IL-6/gp130 binding activity is similar to that detected by the bioassays and again significantly lower than that estimated to be present in the IL-6/sIL-6R complex. Addition of recombinant human IL-6 (rhIL-6) to sera of patients or controls results in a markedly lower increase in the gp130 binding activity in patients than in controls. Moreover, sera from s-JIA patients inhibited in a dose dependent manner the gp130 binding activity assay. These results show that sera from patients with s-JIA contain a factor, or factors, that inhibit(s) the binding of the IL-6/sIL-6R complex to gp130. This inhibitory activity does not appear to be due to soluble gp130, C-reactive protein or autoantibodies to IL-6.     

Involvement of gp130/interleukin-6 receptor transducing component in interleukin-11 receptor

The recently cloned interleukin (IL)-11 displays many biological properties in common with those reported for IL-6. In order to analyze the nature and the functionality of the IL-11 receptor we developed a proliferative assay using the human multifactor-dependent cell line TF1. We showed that a blocking monoclonal antibody GPX7 raised against the gp130/IL-6 receptor transducing subunit was also able to inhibit the IL-11-triggered TF1 line proliferation. In addition, involvement of gp130 in IL-11 signaling was demonstrated by an induction of the transducing protein phosphorylation in response to IL-11, as observed for IL-6. In contrast, the blocking monoclonal antibody B-R6, which recognized the gp80/IL-6 binding subunit, failed to interfere with the IL-11 proliferative signal in the TF1 cell line. Similarly, we did not observe any competition between IL-6 and IL-11 for a putative common binding site on the cell surface. These results suggest that the IL-11 binding component is different from the gp80/IL-6 receptor. In conclusion, IL-11, along with IL-6, leukemia inhibitory factor, oncostatin M and ciliary neurotrophic factor, belongs to the same family of cytokines, using gp130 as a transducing protein.     

Activation of gp130 signaling in vivo by the IL-6 super-agonist K-7 / D-6 accelerates repopulation of lymphoid organs after irradiation

Stimulation of the gp130 signaling pathway by IL-6 is known to contribute significantly to hematopoietic expansion in vitro, mostly in combination with other cytokines. In the present study we have investigated whether a similar effect can be observed also in vivo using shortterm assays in which irradiated mice were analyzed for repopulation of lymphoid organs. Mice were injected with a combination of soluble IL-6Rα either with wild-type (wt) human IL-6 or with an IL-6 variant, called K-7 / D-6, that shows a 70-fold higher IL-6Rα affinity. We observed that while wt IL-6 was able to induce a partial effect only in combination with IL-3, K-7 / D-6 bypassed the need for IL-3 and yielded complete recovery. In lethally irradiated mice reconstituted with syngeneic bone marrow cells K-7 / D-6 strongly accelerated the repopulation of thymus and spleen and hastened blood neutrophil recovery. These results underscore the potential of the gp130 signaling pathway in hematopoietic reconstitution after myeloablative regimens and open the possibility to fully exploit it with a super-active IL-6 variant.     

gp130分子在树突状细胞上表达及其意义

目的 探讨单核细胞向树突状细胞（ＤＣ）分化成熟时,ｇｐ１３０分子在细胞膜上的表达及其意义。方法：从外周血分离得到的单核细胞在含有ＤＣ分化成熟所需的各种因子的培养液中分别培养４ｄ和７ｄ,然后用流式细胞术测定ＤＣ上ｇｐ１３０分子的表达。结果：ｇｐ１３０分子在单核细胞上低表达,经培养分化成熟成为ＤＣ后,ＤＣ上的ｇｐ１３０分子表达被上调,特别是在ＴＮＦα和抗ＣＤ４０刺激型单克隆抗体存在下。结论：ｇｐ１３０